Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine-Reference-Cited by-同舟云学术

Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

Published:2013-06-24 Issue:2 Volume:55 Page:447-449
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Liu Yang,Tabarroki Ali,Billings Steven,Visconte Valeria,Rogers Heesun J.,Hasrouni Edy,Englehaupt Ricki,Kalaycio Matt,Sekeres Mikkael A.,Saunthararajah Yogen,Tiu Ramon V.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.802315

Reference17 articles.

1. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

2. 5-Azacitidine has limited therapeutic activity in myelofibrosis

3. Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

4. AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS.

5. Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies;Cytometry Part B: Clinical Cytometry;2024-01

2. A Case of Sweet's Syndrome Induced at Injection Site of Azacytidine;Nishi Nihon Hifuka;2022-10-01

3. Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review;Annals of Palliative Medicine;2021-08

4. Ultimate Precision: Targeting Cancer But Not Normal Self-Replication;Lung Cancer;2021

5. Targeting sickle cell disease root-cause pathophysiology with small molecules;Haematologica;2019-08-08